@article{00576997c5d94796bec327e2591646d2,
title = "Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition",
abstract = "Osteoporosis-related fractures are undertreated, due in part to misinformation about recommended approaches to patient care and discrepancies among treatment guidelines. To help bridge this gap and improve patient outcomes, the American Society for Bone and Mineral Research assembled a multistakeholder coalition to develop clinical recommendations for the optimal prevention of secondary fracture among people aged 65 years and older with a hip or vertebral fracture. The coalition developed 13 recommendations (7 primary and 6 secondary) strongly supported by the empirical literature. The coalition recommends increased communication with patients regarding fracture risk, mortality and morbidity outcomes, and fracture risk reduction. Risk assessment (including fall history) should occur at regular intervals with referral to physical and/or occupational therapy as appropriate. Oral, intravenous, and subcutaneous pharmacotherapies are efficacious and can reduce risk of future fracture. Patients need education, however, about the benefits and risks of both treatment and not receiving treatment. Oral bisphosphonates alendronate and risedronate are first-line options and are generally well tolerated; otherwise, intravenous zoledronic acid and subcutaneous denosumab can be considered. Anabolic agents are expensive but may be beneficial for selected patients at high risk. Optimal duration of pharmacotherapy is unknown but because the risk for second fractures is highest in the early post-fracture period, prompt treatment is recommended. Adequate dietary or supplemental vitamin D and calcium intake should be assured. Individuals being treated for osteoporosis should be reevaluated for fracture risk routinely, including via patient education about osteoporosis and fractures and monitoring for adverse treatment effects. Patients should be strongly encouraged to avoid tobacco, consume alcohol in moderation at most, and engage in regular exercise and fall prevention strategies. Finally, referral to endocrinologists or other osteoporosis specialists may be warranted for individuals who experience repeated fracture or bone loss and those with complicating comorbidities (eg, hyperparathyroidism, chronic kidney disease).",
keywords = "AGING, ANABOLICS, ANTIRESORPTIVES, OSTEOPOROSIS, SECONDARY FRACTURE PREVENTION",
author = "Conley, {Robert B.} and Gemma Adib and Adler, {Robert A.} and {\AA}kesson, {Kristina E.} and Alexander, {Ivy M.} and Amenta, {Kelly C.} and Blank, {Robert D.} and Brox, {William Timothy} and Carmody, {Emily E.} and Karen Chapman-Novakofski and Clarke, {Bart L.} and Cody, {Kathleen M.} and Cyrus Cooper and Crandall, {Carolyn J.} and Dirschl, {Douglas R.} and Eagen, {Thomas J.} and Elderkin, {Ann L.} and Masaki Fujita and Greenspan, {Susan L.} and Philippe Halbout and Hochberg, {Marc C.} and Muhammad Javaid and Jeray, {Kyle J.} and Kearns, {Ann E.} and Toby King and Koinis, {Thomas F.} and Koontz, {Jennifer Scott} and Martin Ku{\v z}ma and Carleen Lindsey and Mattias Lorentzon and Lyritis, {George P.} and Michaud, {Laura Boehnke} and Armando Miciano and Morin, {Suzanne N.} and Nadia Mujahid and Nicola Napoli and Olenginski, {Thomas P.} and Puzas, {J. Edward} and Stavroula Rizou and Rosen, {Clifford J.} and Kenneth Saag and Elizabeth Thompson and Tosi, {Laura L.} and Howard Tracer and Sundeep Khosla and Kiel, {Douglas P.}",
note = "Funding Information: KA has received consultant fees from Amgen, Eli Lilly, Merck, Renapharma, Sandoz, and UCB; RB has received consultant fees from Novo‐Nordisk, UpToDate, McGraw Hill, and Elsevier; CC has received consultant fees from Amgen, Nestle, Servier, Lilly, and UCB; DK has received consultant fees from Solarea Bio; ML has received consultant fees from Amgen, Lilly, UCB Pharma, Radius Health, Meda, Consilient Health, GE‐Lunar, and Tromp Medical. KS has received consulting fees from Abbvie, Amgen, Ironwood/AstraZeneca, Bayer, Gilead, Horizon, Kowa, Radius, Roche/Genentech, SOBI, Takeda, and Teijin; SG has received grants from Amgen; MKJ has received grants from Amgen; BC has received grants from Shire/Takeda; DK has received grants from National Dairy Council and Radius Health; KS has received grants from Amgen, Ironwood/AstraZeneca, Horizon, SOBI, and Takeda. MH has received royalties from Elsevier as Editor, Rheumatology 7e and as Editor‐in‐Chief, Seminars in Arthritis and Rheumatism, and has received stock or stock options from Wolters Kluwer. RB has received nonfinancial support from Amgen, Abbott Laboratories, Abbvie, and Amgen; BC is a Data Monitoring Board Member for Bristol‐Myers‐Squibb; MH has received personal fees and nonfinancial support from Eli Lilly, Novartis Pharma AG, Pfizer, and Wolters Kluwer as a contributor to UpToDate; KS is Secretary of the American College of Rheumatology. Publisher Copyright: {\textcopyright} 2019 American Society for Bone and Mineral Research",
year = "2020",
month = jan,
day = "1",
doi = "10.1002/jbmr.3877",
language = "English (US)",
volume = "35",
pages = "36--52",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "1",
}